DRUG DISINVESTMENT
IS IT NEEDED AND HOW COULD IT WORK?

November 2018
ISPOR Barcelona

Richard Macaulay PhD, Senior Director, Pricing & Market Access PAREXEL Intl, London , UK
Andrew Walker PhD, former Scottish Medicines Consortium, NHS Greater Glasgow and Clyde; Now: Director, Salus Alba
Detlev Parow MD, Head of Health Care Management, DAK Gesundheit, Hamburg, Germany
Bettina Ryll MD PhD, Founder, and Researcher, Melanoma Patient Network Europe, and Uppsala University, Sweden

© 2018 PAREXEL INTERNATIONAL CORP.

SPEAKERS AND AGENDA

Introduction to drug disinvestment

UK national HTA perspective
On the need, their experiences, & potential mechanisms for drug dis-investment

DE regional payer perspective

Physician & patient perspective

Each panelist will speak for 10 minutes and this will be followed by a 20-minute panel discussion, and 10 minutes of Q&A from the audience.
HEALTHCARE COSTS ARE INCREASING WHILST BUDGETS ARE BEING CONSTRAINED NECESSITATING TRADE-OFFS

Escalating costs + Budgetary pressures

How can high-cost new therapies be reimbursed whilst managing the cost of care?
...AND NEW HIGH-COST THERAPY CLASSES WITH
TRANSFORMATIONAL PATIENT BENEFITS ARE EMERGING

<table>
<thead>
<tr>
<th>Transformative therapy classes</th>
<th>Key features</th>
<th>Consequences</th>
</tr>
</thead>
</table>
| Gene therapies                | Transformational patient benefits
| CAR-T cell therapies          | For diseases with severe unmet needs
|                               | Often in rare patient populations |

These therapies are often **very high-cost**, reflective of their patient benefits, manufacturing costs, and small patient populations

DRUG DISINVESTMENT UNDERLIES TWO POTENTIAL KEY APPROACHES TO ADDRESSING THIS...

1. Re-allocating funding from already reimbursed treatments deemed to be of low value

2. Temporary reimbursement (at a discount) of new treatments until more robust evidence available
...HOWEVER, DESPITE BEING CONCEPTUALLY APPEALING, IN PRACTICE THEY CAN BE CHALLENGING...

- Patient and physician resistance
- Removing clinically effective options for economic reasons
- Linkage between savings and reimbursing new options is not often clear
- Local-level implementation & incumbent financial structures can form barriers
- Lack of patient equity – introducing a time lottery
- Is it even needed? Physician judgement on ‘low value’ options

...AND DISINVESTMENT ATTEMPTS TO DATE HAVE FACED SIGNIFICANT IMPLEMENTATION DIFFICULTIES...

- Conditional financing (Netherlands)
- Warfarin & NOACs
- Erlotinib in EGFR M-? NSCLC (NICE)
- Cancer Drugs Fund (UK) reforms?
…WE WILL ATTEMPT TO ADDRESS THE ISSUE OF DRUG DISINVESTMENT – BOTH ITS NEED & IMPLEMENTATION

DRUG DISINVESTMENT
IS IT NEEDED AND HOW COULD IT WORK?

We will hear perspectives from

UK national HTA  DE regional payer  Physician & patient

Andrew Walker  Detlev Parow  Bettina Ryll